HOLX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Hologic Inc (HOLX) does not present a compelling buy opportunity for a beginner investor with a long-term strategy at this time. While the technical indicators are mildly positive, the lack of significant positive catalysts, a recent analyst downgrade, and declining financial metrics suggest a cautious approach. Holding the stock or exploring other opportunities may be more prudent.
The technical indicators show a mildly bullish trend: MACD is positive and expanding, RSI is neutral at 63.254, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). However, the stock's recent price movements are minimal, with a pre-market change of 0.24% and a regular market change of 0.07%. Key support and resistance levels are close to the current price, indicating limited immediate upside.
Hedge funds are significantly increasing their positions in HOLX, with a 4616.24% increase in buying activity over the last quarter. Gross margin has improved by 1.53% YoY, reaching 57.21%.
Financial performance in Q1 2026 shows a decline in net income (-10.90% YoY) and EPS (-9.20% YoY). There is no recent news or congress trading data to act as a positive catalyst. Stock trend analysis indicates a higher probability of short-term declines (-1.99% in the next week, -1.17% in the next month).
In Q1 2026, revenue increased by 2.54% YoY to $1,047,800,000, but net income dropped by 10.90% YoY to $179,100,000. EPS also declined by 9.20% YoY to 0.79. Gross margin improved slightly by 1.53% YoY to 57.21%. Overall, the financial performance shows mixed results with declining profitability.
Evercore ISI downgraded Hologic to 'In Line' from 'Outperform' and reduced the price target to $78 from $79. This reflects a less optimistic outlook from analysts.
